Coronary/Structural Heart

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Share by Ken Dropiewski on

More in Coronary/Structural Heart:

Share this story

ANN ARBOR, Mich.–(BUSINESS WIRE)–Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients. In addition, the enhanced labels support the use of NEXLET

Ken has been in the cardiac, vascular, and interventional space for over 20 years. He is a Partner with McDermott + Bull Executive Search, recognized by Forbes as one of the industry's best with offices across North America and in Europe. Ken is hired by innovative cardiovascular device and biotech companies to help build their best teams possible at the executive level. Prior to search, Ken had an award winning commercial career at Boston Scientific and Johnson & Johnson to include such prestigious awards as President's Club, Ring Club, and Grand Awards. dropiewski@mbexec.com